699 related articles for article (PubMed ID: 27297606)
1. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.
Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL
Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399
[TBL] [Abstract][Full Text] [Related]
3. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
4. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
[TBL] [Abstract][Full Text] [Related]
5. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
[TBL] [Abstract][Full Text] [Related]
6. A novel transgenic murine model with persistently brittle bones simulating osteogenesis imperfecta type I.
Liu Y; Wang J; Liu S; Kuang M; Jing Y; Zhao Y; Wang Z; Li G
Bone; 2019 Oct; 127():646-655. PubMed ID: 31369917
[TBL] [Abstract][Full Text] [Related]
7. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
[TBL] [Abstract][Full Text] [Related]
8. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM
J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy in the Col1a2
Kaupp S; Horan DJ; Lim KE; Feldman HA; Robling AG; Warman ML; Jacobsen CM
Bone; 2020 Feb; 131():115084. PubMed ID: 31648079
[TBL] [Abstract][Full Text] [Related]
10. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
[TBL] [Abstract][Full Text] [Related]
12. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.
Rauch F; Lalic L; Roughley P; Glorieux FH
J Bone Miner Res; 2010 Jun; 25(6):1367-74. PubMed ID: 19929435
[TBL] [Abstract][Full Text] [Related]
13. Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.
Perosky JE; Khoury BM; Jenks TN; Ward FS; Cortright K; Meyer B; Barton DK; Sinder BP; Marini JC; Caird MS; Kozloff KM
Bone; 2016 Dec; 93():79-85. PubMed ID: 27641475
[TBL] [Abstract][Full Text] [Related]
14. First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome.
Chen F; Guo R; Itoh S; Moreno L; Rosenthal E; Zappitelli T; Zirngibl RA; Flenniken A; Cole W; Grynpas M; Osborne LR; Vogel W; Adamson L; Rossant J; Aubin JE
J Bone Miner Res; 2014 Jun; 29(6):1412-23. PubMed ID: 24443344
[TBL] [Abstract][Full Text] [Related]
15. Exploration of the skeletal phenotype of the
Claeys L; Zhytnik L; Wisse LE; van Essen HW; Eekhoff EMW; Pals G; Bravenboer N; Micha D
Front Endocrinol (Lausanne); 2023; 14():1145125. PubMed ID: 36967771
[TBL] [Abstract][Full Text] [Related]
16. Studies of otic capsule morphology and gene expression in the Mov13 mouse--an animal model of type I osteogenesis imperfecta.
Stankovic KM; Kristiansen AG; Bizaki A; Lister M; Adams JC; McKenna MJ
Audiol Neurootol; 2007; 12(5):334-43. PubMed ID: 17595534
[TBL] [Abstract][Full Text] [Related]
17. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
[TBL] [Abstract][Full Text] [Related]
18. Mutations That Alter the Carboxy-Terminal-Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta Phenotype.
Cundy T; Dray M; Delahunt J; Hald JD; Langdahl B; Li C; Szybowska M; Mohammed S; Duncan EL; McInerney-Leo AM; Wheeler PG; Roschger P; Klaushofer K; Rai J; Weis M; Eyre D; Schwarze U; Byers PH
J Bone Miner Res; 2018 Jul; 33(7):1260-1271. PubMed ID: 29669177
[TBL] [Abstract][Full Text] [Related]
19. Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
Jeong Y; Daghlas SA; Xie Y; Hulbert MA; Pfeiffer FM; Dallas MR; Omosule CL; Pearsall RS; Dallas SL; Phillips CL
J Bone Miner Res; 2018 Oct; 33(10):1760-1772. PubMed ID: 29813187
[TBL] [Abstract][Full Text] [Related]
20. Macroscopic anisotropic bone material properties in children with severe osteogenesis imperfecta.
Albert C; Jameson J; Tarima S; Smith P; Harris G
J Biomech; 2017 Nov; 64():103-111. PubMed ID: 28988680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]